Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

BACKGROUND: RECORD-3 assessed non-inferiority of progression-free survival (PFS) with everolimus vs sunitinib in previously untreated patients with metastatic renal cell carcinoma. Baseline plasma sample collection and randomised design enabled correlation of circulating biomarkers with efficacy. ME...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Voss, Martin H, Chen, David, Marker, Mahtab, Hakimi, A Ari, Lee, Chung-Han, Hsieh, James J, Knox, Jennifer J, Voi, Maurizio, Motzer, Robert J
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2016
Témata:
Translational Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800293/
https://ncbi.nlm.nih.gov/pubmed/26908330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.21
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky